Kernal Biologics vs Warby Parker
Side-by-side comparison of AI visibility scores, market position, and capabilities
AI-designed mRNA 2.0 therapeutics for in vivo CAR-T cancer and autoimmune therapy; $35.8M raised with Amgen Ventures backing advancing KR-335 toward IND filing.
About
Kernal Biologics is a clinical-stage biotech developing AI-designed mRNA therapeutics for cancer and autoimmune diseases — using machine learning to engineer cell-type-specific mRNA sequences that direct therapeutic payloads (including CAR-T gene programs) to the right cells in vivo, enabling off-the-shelf CAR-T cancer therapy without the individualized cell extraction and ex vivo manufacturing process that makes current CAR-T treatments cost $400,000+ and require weeks of production time. The Y Combinator-backed company has raised $35.8 million including a $25 million Series A led by Hummingbird Ventures with participation from Amgen Ventures.
NYSE-listed (WRBY) DTC eyewear brand with $669M revenue and 240+ stores; vertical integration enabling $95-195 glasses competing with LensCrafters while pursuing profitability path after 2021 IPO.
About
Warby Parker is a New York-based direct-to-consumer eyewear company that disrupted the traditional optical retail industry by designing, manufacturing, and selling prescription glasses and sunglasses directly to consumers at $95-$195 price points — compared to $300-500 at traditional optical retailers that added brand markups, optician markups, and optical shop overhead. Listed on NYSE (NYSE: WRBY), Warby Parker generated $669 million in net revenue in fiscal year 2023 and operates 240+ retail stores across the US and Canada alongside its e-commerce and home try-on program.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.